Intellia Therapeutics(NASDAQ) NTLA

Intellia Therapeutics, Inc. creates medicines that fix broken genes inside the human body. These one-time treatments aim to cure rare diseases instead of just managing symptoms. The company focuses on people living with severe genetic conditions and blood disorders.

Rewriting the Human Genetic Code

• Hereditary Angioedema Program: Investigational treatment called lonvo-z that stops the liver from producing a protein that causes painful swelling; wholly owned by the company.
• ATTR Amyloidosis Program: Therapeutic candidate called nex-z designed to prevent a toxic protein from building up in the heart and nerves; co-developed with Regeneron.
• In Vivo Pipeline: Genetic medicines administered directly into a patient through an intravenous infusion to target liver-focused diseases.
• Ex Vivo Pipeline: Engineered cell therapies where cells are removed from the patient, edited in a laboratory, and then returned to the body to fight cancer.

Strategic Partnerships and Growth

• Initiated a rolling biologics license application to the U.S. Food and Drug Administration for lonvo-z in April 2026.
• Raised $194.6 million in net proceeds through a follow-on public offering of common stock in April 2026.
• Established a co-development and co-promotion agreement with Regeneron for the transthyretin amyloidosis program.
• Collaborated with the Novartis Institutes for BioMedical Research to engineer stem cells for treating sickle cell disease.

The First Mover Advantage

Intellia was the first company to advance genome editing treatments that work inside the body into final-stage clinical testing. Its modular platform allows researchers to apply technical data from one genetic program to accelerate the development of others in the pipeline.

Financial Results and Cash Position

• Market capitalization reached $2.3 billion in Q2 2026, up 132.1% year over year.
• Collaboration revenue was $7.7 million in the three months ended June 30, 2026.
• Net loss for the three months ended June 30, 2026, was $106.6 million.
• Cash, cash equivalents, and marketable securities totaled $628.4 million as of June 30, 2026.
• Net cash used in operating activities was $200.5 million during the first six months of 2026.

Bottom Line

Intellia has transitioned from a research organization into a late-stage developer preparing for its first potential commercial product launch. Its shift toward permanent genetic fixes aims to replace lifelong chronic care with one-time therapeutic solutions.